Fig. 3: Kaplan–Meier estimates for (a) PFS and (b) OS for patients treated with naxitamab plus GM-CSF in Trial 201 at data cutoff (December 31, 2021). Efficacy population, n = 52.

a PFS is defined as the time from the first infusion of naxitamab until PD or death, whichever comes first, and censoring occurs at the earliest of the date of last disease evaluation before initiation of new anti-neuroblastoma treatment or last assessment during long-term follow-up. b OS is defined as the time from the first infusion of naxitamab until death, and censoring occurs at the last date where the subjects are known to be alive during long-term follow-up. Source data are provided as a Source Data file. GM-CSF granulocyte-macrophage colony-stimulating factor, OS overall survival, PD progressive disease, PFS progression-free survival.